2nd Quarter - Report
AMRYT PHARMA for AMRYT PHARMA
Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA F NELSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.